BRISTOL-MYERS SQUIBB COMPANY Disposal Group, Including Discontinued Operation, Revenue
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Disposal Group, Including Discontinued Operation, Revenue of $2.83 billion for the 12-month period ending 2009-12-31, per its 10-K filed 2011-02-18.
Discontinued › Income Statement › Other Income
us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue · last filed 2011-02-18
- BRISTOL-MYERS SQUIBB COMPANY disposal group, including discontinued operation, revenue for the quarter ending 2009-12-31 was $715.00M.
- BRISTOL-MYERS SQUIBB COMPANY disposal group, including discontinued operation, revenue for the quarter ending 2009-09-30 was $699.00M.
- BRISTOL-MYERS SQUIBB COMPANY disposal group, including discontinued operation, revenue for the quarter ending 2009-06-30 was $719.00M.
- BRISTOL-MYERS SQUIBB COMPANY disposal group, including discontinued operation, revenue for fiscal 2009 was $2.83B, a 22.60% decline from fiscal 2008.
- BRISTOL-MYERS SQUIBB COMPANY disposal group, including discontinued operation, revenue for fiscal 2008 was $3.65B.
| Period end | Disposal Group, Including Discontinued Operation, Revenue 3 month | Disposal Group, Including Discontinued Operation, Revenue 6 month | Disposal Group, Including Discontinued Operation, Revenue 9 month | Disposal Group, Including Discontinued Operation, Revenue 12 month |
|---|---|---|---|---|
| 2009-12-31 | $715.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $1.41B derived: sum of 2 quarters · filed 2011-02-18 | $2.13B derived: sum of 3 quarters · filed 2011-02-18 | $2.83B 10-K · filed 2011-02-18 |
| 2009-09-30 | $699.00M 10-Q · filed 2010-10-26 | $1.42B derived: sum of 2 quarters · filed 2010-10-26 | $2.11B 10-Q · filed 2010-10-26 | |
| 2009-06-30 | $719.00M 10-Q · filed 2010-07-22 | $1.41B 10-Q · filed 2010-07-22 | ||
| 2008-12-31 | $3.65B 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |